Bacillus Calmette-Guérin (BCG) Vaccine Adverse Events in Victoria, Australia: Analysis of Reports to an Enhanced Passive Surveillance System

Drug Safety

Volumn 38, Issue 1, 2015, Pages 79-86

  Clothier, Hazel J ^a,b   Hosking, Laine ^a   Crawford, Nigel W ^a,b   Russell, Melissa ^b   Easton, Mee Lee ^a   Quinn, Julie Ann ^a   Buttery, Jim P ^a,c,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d SOUTHERN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ARTICLE; AUSTRALIA; BACTERIAL STRAIN; BCG VACCINATION; CHILD; DRUG SURVEILLANCE PROGRAM; ERYTHEMA NODOSUM; FEMALE; HUMAN; INFANT; INJECTION SITE RASH; INJECTION SITE URTICARIA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; SKIN ABSCESS; SKIN NODULE; ADVERSE EFFECTS; EPIDEMIOLOGY; HEALTH SURVEY; IMMUNIZATION; INCIDENCE; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS; YOUNG ADULT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BCG VACCINE; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; TUBERCULOSIS; VICTORIA; YOUNG ADULT;

EID: 84925513511     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0248-6     Document Type: Article

References (35)

1. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec. 2004;79(4):27–38.
2. Barry C, Waring J, Stapledon R, Konstantinos A, National Tuberculosis Advisory Committee CDNA. Tuberculosis notifications in Australia, 2008 and 2009. Commun Dis Intell Q Rep. 2012;36(1):82–94.
3. World Health Organization. Information sheet: observed rate of vaccine reactions bacille Calmette–Guerin (BCG) vaccine. Geneva: World Health Organization; 2012.
4. Ritz N, Curtis N. Mapping the global use of different BCG vaccine strains. Tuberculosis. 2009;89(4):248–51.
5. National Health and Medical Research Council. The Australian immunisation handbook. 9th ed. Australia: Australian Government, Department of Health and Aging; 2008. p. 297–302.
6. National Tuberculosis Advisory Committee. The BCG vaccine: information and recommendations for use in Australia. Commun Dis Intell Q Rep. 2006;30:109–15.
7. The BCG vaccine: information and recommendations for use in Australia. National Tuberculosis Advisory Committee update October 2012. Commun Dis Intell Q Rep. 2013;37(1):E65–72.
8. World Health Organization. Global tuberculosis report. 2013. http://www.who.int/tb/publications/global_report/en/. Accessed 1 June 2014.
9. Fitzgerald MJ, Duclos P. The reporting and management of adverse reactions to bacillus Calmette–Guerin (BCG) vaccination. Can Dis Wkly Rep (Rapport hebdomadaire des maladies au Canada). 1991;17(19):98–100.
10. Murphy D, Corner LA, Gormley E. Adverse reactions to Mycobacterium bovis bacille Calmette–Guerin (BCG) vaccination against tuberculosis in humans, veterinary animals and wildlife species. Tuberculosis. 2008;88(4):344–57.
11. Grange J. Complications of bacille Calmette–Guérin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health. 1998;1:84–8.
12. Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S, Altare F, et al. Idiopathic disseminated bacillus Calmette–Guerin infection: a French national retrospective study. Pediatrics. 1996;98(4 Pt 1):774–8.
13. Deeks SL, Clark M, Scheifele DW, Law BJ, Dawar M, Ahmadipour N, et al. Serious adverse events associated with bacille Calmette–Guerin vaccine in Canada. Pediatr Infect Dis J. 2005;24(6):538–41.
14. Dawar M, Clark M, Deeks SL, Walop W, Ahmadipour N. A fresh look at an old vaccine: does BCG have a role in 21st century Canada? Int J Circumpolar Health. 2004;63(Suppl 2):230–6.
15. Marciano BE, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133(4):1134–41.
16. Turnbull FM, McIntyre PB, Achat HM, Wang H, Stapledon R, Gold M, et al. National study of adverse reactions after vaccination with bacille Calmette–Guerin. Clinical Infect Dis. 2002;34(4):447–53.
17. Department of Health and Ageing. Tuberculosis (BCG) vaccine: urgent medicine recall. 2012. http://www.tga.gov.au/safety/recalls-medicine-tuberculosis-bcg-vaccine-120620.htm. Accessed 29 Sept 2013.
18. Department of Health and Ageing. Tuberculosis bacillus Calmette–Guerin (BCG) vaccine recall fact sheet. Health alerts. 2012. http://www.health.gov.au/internet/main/publishing.nsf/Content/bcg-factsheet.htm. Accessed 26 Oct 2013.
19. Department of Health Victoria. Bacille Calmette–Geurin (BCG) vaccine for tuberculosis: frequently asked questions. In: Department of Health, editor. Information for health professionals. Melbourne: Victoria; 2012.
20. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012.
21. Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res (Fortschritte der Tuberkuloseforschung Progres de l’exploration de la tuberculose). 1984;21:107–93.
22. Australian Bureau of Statistics. Australian demographic statistics, June 2012, estimated resident population by single year of age, Victoria. 2012. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun2012?OpenDocument. Accessed 23 May 2014.
23. Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell. 2011;35(4):294–8.
24. Department of Health Victoria. Adverse events reporting. immunisation. 2012. http://www.health.vic.gov.au/immunisation/saefvic.htm.
25. FitzGerald JM. Management of adverse reactions to bacille Calmette–Guerin vaccine. Clin Infect Dis. 2000;31(Suppl 3):S75–6.
26. Clothier HJ, Selvaraj G, McMinn A, Lewis G, Crawford NW, Buttery JP. SAEFVIC: surveillance of adverse events following immunisation (AEFI) in Victoria, 2012 Vic Infect Dis Bull. 2013;16(4) (in press).
27. Al Awaidy S, Bawikar S, Prakash KR, Al Rawahi B, Mohammed AJ. Surveillance of adverse events following immunization: 10 years’ experience in Oman. East Mediterr Health J. 2010;16(5):474–80.
28. Bongaarts J. The implementation of preferences for male offspring. Popul Dev Rev. 2013;39(2):23.
29. Golebiowska M, Andrzejewska E, Stryjewska I, Baranowska H, Drazkiewicz A. Adverse events following BCG vaccination in infants and children up to 36 months of age. Przegl Epidemiol. 2008;62(1):71–5.
30. Dommergues MA, de La Rocque F, Guy C, Lecuyer A, Jacquet A, Guerin N, et al. Local and regional adverse reactions to BCG-SSI vaccination: a 12-month cohort follow-up study. Vaccine. 2009;27(50):6967–73.
31. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173–80.
32. Linehan MF, Nurmatov U, Frank TL, Niven RM, Baxter DN, Sheikh A. Does BCG vaccination protect against childhood asthma? Final results from the Manchester Community Asthma Study retrospective cohort study and updated systematic review and meta-analysis. J Allergy Clin Immunol. 2014;133(3):688–95 e14.
33. Freyne B, Curtis N. Does neonatal BCG vaccination prevent allergic disease in later life? Archiv Dis Child. 2014;99(2):182–4.
34. Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, Gie RP, et al. Danish bacille Calmette–Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis. 2003;37(9):1226–33.
35. Lugosi L. BCG and immunotherapy for tumors. Prevention of adverse effects of BCG vaccination. Orvosi hetilap. 1972;113(13):757–9.